Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
Iterum Therapeutics (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing next-generation oral antibiotics, will participate in the 26th Annual H.C. Wainwright Global Investment Conference from September 9-11, 2024, in New York City. CEO Corey Fishman will present on September 10 at 8:30 AM ET and host investor meetings.
The conference, held at the Lotte New York Palace Hotel, is open to qualified investors. Iterum's management will be available for one-on-one meetings on September 10. A replay of the webcast presentation will be accessible on Iterum's website in the Events & Presentations section after the event.
Iterum Therapeutics (Nasdaq: ITRM), un'azienda farmaceutica in fase clinica che sviluppa antibiotici orali di nuova generazione, parteciperà al 26° Annual H.C. Wainwright Global Investment Conference che si svolgerà dal 9 all'11 settembre 2024 a New York. Il CEO Corey Fishman presenterà il 10 settembre alle 8:30 AM ET e ospiterà incontri con gli investitori.
La conferenza, che si terrà presso il Lotte New York Palace Hotel, è aperta a investitori qualificati. La direzione di Iterum sarà disponibile per incontri individuali il 10 settembre. Una registrazione della presentazione in webcast sarà accessibile sul sito web di Iterum nella sezione Eventi e Presentazioni dopo l'evento.
Iterum Therapeutics (Nasdaq: ITRM), una compañía farmacéutica en etapa clínica que desarrolla antibióticos orales de nueva generación, participará en la 26ª Conferencia Anual de Inversión Global H.C. Wainwright del 9 al 11 de septiembre de 2024 en Nueva York. El CEO Corey Fishman presentará el 10 de septiembre a las 8:30 AM ET y llevará a cabo reuniones con inversores.
La conferencia, que se celebrará en el Lotte New York Palace Hotel, está abierta a inversores calificados. La dirección de Iterum estará disponible para reuniones uno a uno el 10 de septiembre. Una repetición de la presentación por webcast estará accesible en el sitio web de Iterum en la sección de Eventos y Presentaciones después del evento.
Iterum Therapeutics (Nasdaq: ITRM), 차세대 경구 항생제를 개발하는 임상 단계 제약 회사가 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 제26회 H.C. Wainwright 글로벌 투자 컨퍼런스에 참가합니다. CEO Corey Fishman은 9월 10일 오전 8:30 ET에 발표하며 투자자 미팅을 주최할 예정입니다.
롯데 뉴욕 팰리스 호텔에서 열리는 이 컨퍼런스는 자격을 갖춘 투자자들에게 열려 있습니다. Iterum의 경영진은 9월 10일 1:1 미팅을 위해 참석할 것입니다. 이벤트가 끝난 후 Iterum 웹사이트의 이벤트 및 발표 섹션에서 웹캐스트 발표 재생이 가능합니다.
Iterum Therapeutics (Nasdaq: ITRM), une entreprise pharmaceutique en phase clinique développant des antibiotiques oraux de prochaine génération, participera à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright qui se tiendra du 9 au 11 septembre 2024 à New York. Le PDG Corey Fishman présentera le 10 septembre à 8h30 ET et animera des réunions avec des investisseurs.
La conférence, qui se déroulera au Lotte New York Palace Hotel, est ouverte aux investisseurs qualifiés. La direction d'Iterum sera disponible pour des réunions en tête-à-tête le 10 septembre. Un replay de la présentation en webdiffusion sera accessible sur le site d'Iterum dans la section Événements et Présentations après l'événement.
Iterum Therapeutics (Nasdaq: ITRM), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Antibiotika der nächsten Generation entwickelt, wird am 26. jährlichen H.C. Wainwright Global Investment Conference teilnehmen, die vom 9. bis 11. September 2024 in New York City stattfindet. CEO Corey Fishman wird am 10. September um 8:30 Uhr ET präsentieren und Investorenbesprechungen leiten.
Die Konferenz findet im Lotte New York Palace Hotel statt und ist für qualifizierte Investoren geöffnet. Das Management von Iterum wird am 10. September für persönliche Gespräche zur Verfügung stehen. Eine Wiederholung der Webcast-Präsentation wird nach der Veranstaltung auf der Website von Iterum im Bereich Veranstaltungen & Präsentationen verfügbar sein.
- None.
- None.
DUBLIN, Ireland and CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced that Corey Fishman, Iterum's Chief Executive Officer, will present and host investor meetings at the 26th Annual H.C. Wainwright Global Investment Conference held September 9 to September 11, 2024, at the Lotte New York Palace Hotel.
Admission to H.C. Wainwright's conference is for qualified investors. Iterum will be giving a presentation at 8:30 am ET on September 10, 2024. Management will also be available for one-on-one meetings onsite on September 10, 2024.
H.C. Wainwright 26th Annual Global Investment Conference, New York, NY
Presentation Date: Tuesday, September 10, 2024
Presentation Time: 8:30 AM ET
1x1 Meetings: Please contact your HCW representative
The webcast presentation replay will be available for viewing on the Events & Presentations section of Iterum’s website following the presentation.
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has submitted an NDA for oral sulopenem for the treatment of uncomplicated urinary tract infections in adult women, which has been accepted for review by the U.S. Food and Drug Administration and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://www.iterumtx.com.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
When is Iterum Therapeutics (ITRM) presenting at the H.C. Wainwright Global Investment Conference?
Where is the 26th Annual H.C. Wainwright Global Investment Conference being held?
Will Iterum Therapeutics (ITRM) be available for one-on-one meetings at the conference?
How can investors access the replay of Iterum Therapeutics' (ITRM) presentation?
What is the focus of Iterum Therapeutics (ITRM) as a company?
